Brussels assumes Janssen will not deliver promised doses in Q2

The European Commission has recognized this Wednesday that the pharmaceutical Jannsen will not be able to distribute to the EU countries the 55 million doses of its vaccine that were scheduled for the second quarter of the year. For its part, the US continues to trust another company, Moderna, and signs a new contract for 200 million doses.

“We believe that the company will not be in a position to deliver the 55 million doses planned for the end of this quarter. Member States have expressed great concern about this problem with deliveries,” the spokesman for Community Executive Health Stefan de Keersmaecker.

The spokesman, who has not been able to clarify a “concrete figure” on the doses that the pharmaceutical subsidiary of Johnson & Johnson will be able to distribute before the end of June, has assured that both Brussels and the capitals maintain a “close contract” with Janssen for ” To analize the situation”.

According to the website of the European Center for Disease Control and Prevention (ECDC, for its acronym in English), Janssen has delivered within 15 days of the end of the quarter about 12 million units of its single-dose vaccine to the European countries of the 55 million agreed between April and June.

In any case, De Keersmaecker has guaranteed that the confirmed deliveries of the rest of the companies allow the EU to meet its goal of having vaccinated 70% of the European adult population before the end of the summer.

Last Friday, the European Medicines Agency (EMA) issued a statement in which it clarified that the batch of contaminated Janssen vaccines in a production plant in the United States did not affect units that had to be sent to the Community market.

However, as a precautionary measure and “to safeguard the quality of the vaccines”, the European health authorities recommended not to distribute the doses containing the active substance produced in the same production plant where the contamination took place.

Purchase from the US to Moderna

The biotech Moderna announced on Wednesday that the United States Government has purchased another 200 million doses of its vaccine against covid-19 that could be used to immunize children, if that use is approved, or as a booster.

In a statement, the Massachusetts-based company indicated that the US has purchased a total of 500 million doses, of which it has delivered 217 million, and estimated that it will supply 110 million in the fourth quarter of 2021 and 90 million in the first of 2022.

“We appreciate the collaboration with the US Government for these additional doses of Moderna’s covid-19 vaccine, which could be used for primary vaccinations, including children, or possibly as a booster if necessary to continue defeating the pandemic. “stated CEO St├ęphane Bancel.

“We continue to be proactive as the virus evolves, taking advantage of the flexibility of our mRNA platform to stay ahead of emerging variants,” he added.

The purchase agreement includes the option to other candidate vaccine projects against Moderna’s coronavirus, according to the note.

The biotechnology company requested an emergency authorization in the US a week ago so that its product can be used in adolescents between 12 and 18 years old, which would be in addition to the permission it already has to vaccinate the adult population.

After hearing the news, Moderna shares fell 1.04% on the New York Stock Exchange. Since the beginning of the year, the listed company has appreciated by about 92%.


Source link


Please enter your comment!
Please enter your name here